肥胖是早期类风湿关节炎治疗反应不佳的危险因素:NORD-STAR研究
该报告基于NORD-STAR随机纵向试验中793例未治疗早期类风湿关节炎患者,按基线BMI分层,肥胖定义为BMI≥30 kg/m2。随访至48周,基线肥胖者疾病活动度更高,达到CDAI、SDAI缓解及DAS28-CRP<2.6的可能性更低(SDAI HR 0.77,95%CI 0.62至0.97;DAS28-CRP<2.6 HR 0.78,95%CI 0.64至0.95),且不受治疗分组影响。
要点
- 793例未治疗早期RA中161例(20%)基线肥胖(BMI≥30 kg/m2)。
- 基线肥胖者随访期疾病活动度高于BMI较低者,尽管基线疾病活动度相似。
- 肥胖与48周内治疗反应达标可能性降低相关,且不受随机治疗分组影响。
核心结论
- 在未治疗早期RA患者中随访至48周,肥胖与良好治疗反应可能性降低相关,且与所接受的随机治疗类型无关。
研究设计与样本
- 本报告来自NORD-STAR随机纵向试验,纳入793例未治疗早期RA患者,均在基线评估BMI,肥胖定义为BMI≥30 kg/m2。
- 所有参与者按1:1:1:1随机分配至四个治疗组:活动性常规治疗、certolizumab-pegol、abatacept和tocilizumab。
- 在基线及第8、12、24、48周随访时进行临床和实验室测量。
主要发现
- 793例中161例(20%)基线肥胖。
- 随访期间,基线肥胖者疾病活动度高于BMI较低者,尽管基线疾病活动度相似。
- 生存分析显示,肥胖与随访至48周内达到治疗反应的可能性降低相关:CDAI缓解HR 0.84(95%CI 0.67至1.05);SDAI HR 0.77(95%CI 0.62至0.97);DAS28-CRP<2.6 HR 0.78(95%CI 0.64至0.95)。
- 肥胖对治疗反应的影响不受治疗分组影响。
关键数值与推荐
- 肥胖定义为BMI≥30 kg/m2。
- 主要终点为基于CDAI和SDAI缓解及DAS28-CRP<2.6的治疗反应,按BMI分层。
- CDAI缓解HR 0.84(95%CI 0.67至1.05);SDAI HR 0.77(95%CI 0.62至0.97);DAS28-CRP<2.6 HR 0.78(95%CI 0.64至0.95)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This report from the NORD-STAR (Nordic Rheumatic Diseases Strategy Trials and Registries) trial aimed to determine if obesity is associated with response to conventional and biological antirheumatic treatment in early rheumatoid arthritis (RA). METHODS: This report included 793 participants with untreated early RA from the randomised, longitudinal NORD-STAR trial, all of whom had their body mass index (BMI) assessed at baseline. Obesity was defined as BMI ≥30 kg/m2. All participants were randomised 1:1:1:1 to one of four treatment arms: active conventional treatment, certolizumab-pegol, abatacept and tocilizumab. Clinical and laboratory measurements were performed at baseline and at 8, 12, 24 and 48-week follow-up. The primary endpoint for this report was response to treatment based on Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI) remission and Disease Activity Score with 28 joints using C-reactive protein (DAS28-CRP) <2.6 stratified by BMI. RESULTS: Out of 793 people included in the present report, 161 (20%) had obesity at baseline. During follow-up, participants with baseline obesity had higher disease activity compared with those with lower BMI, despite having similar disease activity at baseline. In survival analyses, obesity was associated with a lower likelihood of achieving response to treatment during follow-up for up to 48 weeks (CDAI remission, HR 0.84, 95% CI 0.67 to 1.05; SDAI, HR 0.77, 95% CI 0.62 to 0.97; DAS28-CRP <2.6, HR 0.78, 95% CI 0.64 to 0.95). The effect of obesity on response to treatment was not influenced by the treatment arms. CONCLUSION: In people with untreated early RA followed up for up to 48 weeks, obesity was associated with a lower likelihood of good treatment response, irrespective of the type of randomised treatment received. TRIAL REGISTRATION NUMBER: NCT01491815.
引用
- Dubovyk V, Vasileiadis GK, Fatima T, et al. Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study. RMD Open. 2024. PMID: 38580350. doi:10.1136/rmdopen-2024-004227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。